Press release
Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 5+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
* In August 2025, Boehringer Ingelheim announced a study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part.
* DelveInsight's Cough in Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cough in Idiopathic Pulmonary Fibrosis treatment.
* The leading Cough in Idiopathic Pulmonary Fibrosis Companies such as Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
* Promising Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate) and others.
Learn how leading Cough in Idiopathic Pulmonary Fibrosis Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs Profile
* Haduvio (nalbuphine ER): Trevi Therapeutics
Haduvio (nalbuphine ER) has a novel approach to chronic cough by working on two important receptors that are critical mediators of cough, in both the central and peripheral nerves. Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body's mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF).
The Cough in Idiopathic Pulmonary Fibrosis Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
* Cough in Idiopathic Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.
From early-stage research to late-phase Cough in Idiopathic Pulmonary Fibrosis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Cough in Idiopathic Pulmonary Fibrosis Treatment Drugs [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cough in Idiopathic Pulmonary Fibrosis Companies
Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay updated with the latest Cough in Idiopathic Pulmonary Fibrosis Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
* Coverage- Global
* Cough in Idiopathic Pulmonary Fibrosis Companies- Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
* Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies- Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate) and others.
* Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Cough in Idiopathic Pulmonary Fibrosis (IPF): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cough in Idiopathic Pulmonary Fibrosis (IPF)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Mid Stage Products (Phase II)
* Haduvio (nalbuphine ER): Trevi Therapeutics
* Early Stage Products (Phase I)
* Drug name: Company name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
* Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Products
* Cough in Idiopathic Pulmonary Fibrosis (IPF)- Unmet Needs
* Cough in Idiopathic Pulmonary Fibrosis (IPF)- Market Drivers and Barriers
* Cough in Idiopathic Pulmonary Fibrosis (IPF)- Future Perspectives and Conclusion
* Cough in Idiopathic Pulmonary Fibrosis (IPF) Analyst Views
* Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cough-in-idiopathic-pulmonary-fibrosis-pipeline-outlook-report-2025-key-5-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 5+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4140711 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Cough
Dog's Cough Intensifies Due to Temperature Difference, Trusted Dog Cough Medicin …
Image: https://www.getnews.info/uploads/e50cc9d317e270f5e3e669a0339f0b84.jpg
During periods of significant temperature fluctuations, not only humans but also many dogs are prone to experiencing coughing symptoms. Differences between daytime and nighttime temperatures, dry weather, and frequent transitions between indoor and outdoor environments can directly affect the bronchial health of dogs, making them more susceptible to respiratory problems. In particular, sudden changes in weather can make a dog's respiratory system sensitive, resulting in noticeable coughing symptoms.
Coughing in…
Cough Care Advance launches Cough Care Advance, an innovative, kid-friendly coug …
Cough Care Advance is introducing an innovative, kid-friendly cough remedy that provides safe, natural, and long-lasting relief.
Parents know how difficult it can be when children are battling a stubborn cough. Whether it's keeping them up at night or disrupting their day at school, finding an effective and gentle solution is a top priority. That's why Cough Care Advance is introducing an innovative, kid-friendly cough remedy that provides safe, natural, and…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Refractory Chronic Cough Therapeutics Market - Pioneering Solutions for Persiste …
Newark, New Castle, USA - new report, titled Refractory Chronic Cough Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Refractory Chronic Cough Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Refractory Chronic Cough Therapeutics market. The report offers…
Cough Systems Market
Global cough systems market size is expected to be worth roughly USD 192.8 million by 2030, growing at a CAGR of more than 8.6% during the projected timeframe of 2022-2030, according to Ameco Research
Cough systems are appliances that assist to cleanse the lungs of excessive cough output by changing the flow patterns, which enhances the airway patency and helps to establish and promote alveolar growth. Excessive coughing produces severe lung…
Global Cough Syrup Market Size, Cough Syrup Market Share, Cough Syrup Market Gro …
The Global "Cough Syrup Market" 2022 research report presents an in-depth analysis of the Cough Syrup Market size, growth, share, segments, manufacturers, and forecast, competition landscape and growth opportunity. The research's goal is to provide market data and strategic insights to help decision-makers to make educated investment decisions while also identifying potential gaps and development possibilities.We also analysed the impact of COVID-19 (Corona Virus) on the product industry chain based…
